Abstract The Influenza A virus (IAV) is a zoonotic pathogen that infects humans and various
animal species. Infection with IAV can cause fever, anorexia, and dyspnea and is often …

Influenza A virus (IAV) has developed elegant strategies to utilize cellular proteins and
pathways to promote replication and evade the host antiviral response. Identification of …

Virus-Like Particles (VLPs) are nanostructures that share conformation and self-assembly
properties with viruses, but lack a viral genome and therefore the infectious capacity. In this …

Background New approaches are urgently needed to fight influenza viral infection. Previous
research has shown that zirconia nanoparticles can be used as anticancer materials, but …

As the therapeutic agent for antiviral applications, the clinical use of oseltamivir is limited
with the appearance of drug-resistant viruses. It is important to explore novel anti-influenza …

The emergence of the pandemic 2009 H1N1 influenza virus has become a world-wide
health concern. As drug resistance appears, a new generation of therapeutic strategies will …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus
disease 2019 (COVID-19) emerged in late 2019 and resulted in a devastating pandemic …

Influenza A virus (IAV) is a major respiratory pathogen that causes seasonal and pandemic
flu, being a threat to global health. Various viral and cellular factors have been characterized …

Influenza A viruses (IAV), significant respiratory pathogenic agents, cause seasonal
epidemics and global pandemics in intra-and interannual cycles. Despite effective therapies …

Albeit microRNAs (miRNAs) have become increasingly appreciated for their essential roles
in innate immune responses to viral infections; however, it is unknown how host miRNAs …